Short Interest in Capstone Therapeutics Corp. (NASDAQ:CAPS) Drops By 48.0%

Capstone Therapeutics Corp. (NASDAQ:CAPS) saw a significant drop in short interest in May. As of May 15th, there was short interest totaling 103,447 shares, a drop of 48.0% from the April 30th total of 199,019 shares. Based on an average daily trading volume, of 324,989 shares, the days-to-cover ratio is currently 0.3 days. Approximately 1.3% of the shares of the company are sold short.

Institutional Trading of Capstone Therapeutics

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC purchased a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 2.55% of the company’s stock.

Capstone Therapeutics Price Performance

Capstone Therapeutics stock traded up $0.02 during midday trading on Monday, reaching $0.34. The company’s stock had a trading volume of 747,304 shares, compared to its average volume of 2,601,567. Capstone Therapeutics has a 52 week low of $0.26 and a 52 week high of $2.07. The company has a current ratio of 0.95, a quick ratio of 0.29 and a debt-to-equity ratio of 0.79. The business has a 50-day moving average price of $0.47 and a 200-day moving average price of $0.63. The stock has a market cap of $4.24 million, a PE ratio of -0.10 and a beta of -1.54.

Capstone Therapeutics (NASDAQ:CAPS) last released its earnings results on Wednesday, May 20th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). The business had revenue of $12.64 million during the quarter, compared to the consensus estimate of $10.80 million. Capstone Therapeutics had a negative net margin of 41.26% and a negative return on equity of 114.15%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Capstone Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Wednesday, May 20th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of “Sell”.

Capstone Therapeutics Company Profile

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.